VTVT (vTv Therapeutics) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


VTVT vTv Therapeutics Inc VTVT
35 GF Score
Price $36.82
GF Value $7,827.31
Valuation Significantly Undervalued
View Full Analysis

What is vTv Therapeutics Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

vTv Therapeutics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

VTVT vs CRDF, GUTS, ACOG: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, vTv Therapeutics's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

vTv Therapeutics Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, vTv Therapeutics's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where vTv Therapeutics's Margin of Safety % (DCF Earnings Based) falls into.


VTVT
35GF Score
vTv Therapeutics Inc VTVT
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is vTv Therapeutics (VTVT) Overvalued in 2026?

Based on GuruFocus' analysis, vTv Therapeutics stock appears to be undervalued. The current stock price of $36.82 is trading 99.5% below its estimated GF Value™ of $7,827.31. GuruFocus considers vTv Therapeutics to be Significantly Undervalued.

Key valuation signals for VTVT:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $7,827.31 vs. price of $36.82 (99.5% below fair value)
  • GF Score™: 35/100

No single metric tells the full story. See the VTVT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

vTv Therapeutics Business Description

Address 3980 Premier Drive, Suite 110, High Point, NC, USA, 27265
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
35GF Score

Get the complete analysis for VTVT

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$36.82
Price
$7,827.31
GF Value